标题：硫酸镁联合阿司匹林方案用于妊高征的疗效及安全性

      作者：王敏，张娟娟，王小凤    西北妇女儿童医院产科，陕西 西安 710061

      卷次： 2021年32卷23期

      【摘要】 目的 探究硫酸镁联合阿司匹林治疗妊娠期高血压疾病(妊高征)的临床效果及安全性。方法 选取2018年2月至2020年11月西北妇女儿童医院产科收治的120例妊高征患者为研究对象，按照住院顺序将患者分为对照组和观察组，每组60例，对照组患者采用阿司匹林单一用药治疗；观察组则采取硫酸镁联合阿司匹林用药治疗，疗程均为4 d。治疗后，比较两组患者的临床疗效，治疗前后的舒张压(DBP)及收缩压(SBP)水平，治疗前后尿常规中尿蛋白(PRO)、胆红素(BIL)指标，治疗前后血流动力学参数中的中心静脉压(CVP)、心排血量(CO)、左心室射血分数(LVEF)水平及不良反应发生情况。结果 观察组患者的临床治疗总有效率为 96.67%，明显高于对照组的81.67%，差异有统计学意义(P<0.05)；治疗后，两组患者的血压均明显降低，且观察组患者的DBP和 SBP分别为(85.43±2.19) mmHg、(145.75±8.11) mmHg，明显低于对照组的(89.66±2.14) mmHg、(150.67±7.78) mmHg，差异均有统计学意义(P<0.05)；治疗后，观察组患者24 h内的PRO和BIL分别为(132.25±5.21) mg、(11.38±1.34) μmol/L，明显低于对照组的(145.35±5.25) mg、(13.12±1.21) μmol/L，差异均有统计学意义(P<0.05)；治疗后，两组患者的血流动力学参数均明显好转，且观察组患者的CVP、CO和LVEF分别为(114.36±3.47) mmH2O、(71.35±5.33) mL/次、(73.36±5.19)%，明显优于对照组的(117.22±3.35) mmH2O、(68.35±5.26) mL/次、(70.35±5.20)%，差异均有统计学意义(P<0.05)；观察组患者的不良反应发生率为13.33%，与对照的11.67%比较差异无统计学意义(P>0.05)。结论 硫酸镁联合阿司匹林用于治疗妊高征，可有效降低患者血压，改善尿常规和血流动力学参数，且安全性好，综合疗效较好。
      【关键词】 妊娠期高血压疾病；硫酸镁；阿司匹林；单一用药；联合用药；安全性
      【中图分类号】 R714.24+6 【文献标识码】 A 【文章编号】 1003—6350（2021）23—3079—04

Efficacy and safety of magnesium sulfate combined with aspirin in the treatment of pregnancy-inducedhypertension.
WANG Min, ZHANG Juan-juan, WANG Xiao-feng. Department of Obstetrics, Northwest Women andChildren's Hospital, Xi'an 710061, Shaanxi, CHINA
【Abstract】 Objective To explore the clinical effect and safety of magnesium sulfate combined with aspirin inthe treatment of pregnancy-induced hypertension (PIH). Methods A total of 120 PIH patients treated in Department ofObstetrics, Northwest Women and Children's Hospital from February 2018 to November 2020 were selected and divid-ed into the control group (n=60) and the observation group (n=60) according to the order of hospitalization. The con-trol group was treated with aspirin monotherapy, and the observation group was treated with magnesium sulfate com-bined with aspirin. The course of treatment lasted 4 days. After treatment, the clinical efficacy were compared, and thechanges of diastolic blood pressure (DBP) and systolic blood pressure (SBP) before and after treatment, the changes ofurine protein (PRO), bilirubin (BIL) before and after treatment, the changes of central venous pressure (CVP), cardiacoutput (CO), left ventricular ejection fraction (LVEF) before and after treatment, and the occurrence of adverse reac-tions were compared between the two groups. Results The clinical total effective rate of the observation group was96.67%, which was significantly higher than 81.67% of the control group (P<0.05); after treatment, the blood pressuredecreased significantly in both groups, the DBP and SBP of the observation group were (86.43 ± 2.19) mmHg and(145.75±8.11) mmHg, which were significantly better than (89.66±2.14) mmHg and (150.67±7.78) mmHg of the con-trol group (P<0.05). After treatment, the 24 h PRO and BIL of the observation group were (132.25 ± 5.21) mg and(11.38±1.34) μmol/L, respectively, which were significantly lower than (145.35±5.25) mg and (13.12±1.21) μmol/L ofthe control group (P<0.05). After treatment, the hemodynamic parameters of the two groups were significantly im-proved, and CVP, CO, LVEF were (114.36±3.47) mmH2O, (71.35±5.33) mL/time, (73.36±5.19)%, respectively, whichwere significantly better than (117.22±3.35) mmH2O, (68.36±5.19) mL/time, (70.35±5.20)% in the control group (P<0.05). The incidence of adverse reactions in the observation group was 13.33%, which showed no statistically significantdifference as compared with 11.67% in the control group (P>0.05). Conclusion Magnesium sulfate combined with as-pirin in the treatment of pregnancy-induced hypertension can effectively reduce blood pressure, improve urinary routineand hemodynamic parameters, and has good safety and comprehensive curative effect.
      【Key words】 Pregnancy-induced hypertension; Magnesium sulphate; Aspirin; Single drug use; Combinationmedication; Security